athenahealth, Inc. (NASDAQ:ATHN) had its price objective reduced by analysts at Robert W. Baird from $170.00 to $155.00 in a research report issued to clients and investors on Sunday. The firm currently has an “outperform” rating on the health services provider’s stock. Robert W. Baird’s price target suggests a potential upside of 22.41% from the stock’s previous close.

A number of other research firms have also recently issued reports on ATHN. Piper Jaffray Companies reissued a “buy” rating and set a $152.00 price objective on shares of athenahealth in a research report on Friday, July 14th. Oppenheimer Holdings, Inc. reissued a “buy” rating and set a $184.00 price objective on shares of athenahealth in a research report on Friday. BidaskClub cut shares of athenahealth from a “hold” rating to a “sell” rating in a research report on Wednesday, July 12th. First Analysis cut shares of athenahealth from an “equal weight” rating to an “underweight” rating and increased their price objective for the stock from $99.00 to $125.00 in a research report on Monday, July 24th. Finally, UBS AG reissued a “positive” rating and set a $175.00 price objective (up previously from $157.00) on shares of athenahealth in a research report on Monday, July 24th. Two investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have issued a buy rating to the company’s stock. athenahealth presently has a consensus rating of “Hold” and an average target price of $144.91.

athenahealth (ATHN) traded up 0.46% on Friday, reaching $126.62. The company’s stock had a trading volume of 941,510 shares. The company has a market cap of $5.06 billion, a P/E ratio of 160.69 and a beta of 1.76. The stock’s 50 day moving average price is $125.37 and its 200 day moving average price is $130.33. athenahealth has a 12 month low of $90.11 and a 12 month high of $158.66.

athenahealth (NASDAQ:ATHN) last issued its quarterly earnings results on Thursday, October 19th. The health services provider reported $0.56 EPS for the quarter, beating the Zacks’ consensus estimate of $0.50 by $0.06. The business had revenue of $304.60 million for the quarter, compared to analysts’ expectations of $310.52 million. athenahealth had a net margin of 2.65% and a return on equity of 6.94%. The business’s quarterly revenue was up 10.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.60 earnings per share. Equities research analysts forecast that athenahealth will post $1.97 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This article was originally published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/10/22/athenahealths-athn-buy-rating-reiterated-at-robert-w-baird.html.

In other athenahealth news, insider Daniel P. Haley sold 1,583 shares of the stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $124.56, for a total value of $197,178.48. Following the completion of the sale, the insider now owns 13,408 shares in the company, valued at approximately $1,670,100.48. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Jonathan Bush sold 4,000 shares of the stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $143.31, for a total transaction of $573,240.00. Following the completion of the sale, the chief executive officer now owns 319,807 shares of the company’s stock, valued at approximately $45,831,541.17. The disclosure for this sale can be found here. In the last quarter, insiders sold 15,783 shares of company stock valued at $2,132,924. Company insiders own 3.20% of the company’s stock.

A number of large investors have recently bought and sold shares of ATHN. Janus Henderson Group PLC purchased a new stake in shares of athenahealth during the 2nd quarter worth approximately $713,856,000. BlackRock Inc. increased its stake in shares of athenahealth by 30,642.6% during the 1st quarter. BlackRock Inc. now owns 1,599,847 shares of the health services provider’s stock worth $180,286,000 after purchasing an additional 1,594,643 shares during the last quarter. Elliott Management Corp purchased a new stake in shares of athenahealth during the 2nd quarter worth approximately $52,706,000. Clearbridge Investments LLC increased its stake in shares of athenahealth by 61.8% during the 1st quarter. Clearbridge Investments LLC now owns 908,505 shares of the health services provider’s stock worth $102,379,000 after purchasing an additional 347,133 shares during the last quarter. Finally, Capital Research Global Investors increased its stake in shares of athenahealth by 15.5% during the 2nd quarter. Capital Research Global Investors now owns 2,041,714 shares of the health services provider’s stock worth $286,963,000 after purchasing an additional 273,660 shares during the last quarter.

athenahealth Company Profile

athenahealth, Inc provides network-based medical record, revenue cycle, patient engagement, care coordination and population health services. The Company also offers Epocrates and other point-of-care mobile applications. The Company delivers majority of its service offerings through a single instance of cloud-based software, athenaNet.

Analyst Recommendations for athenahealth (NASDAQ:ATHN)

Receive News & Ratings for athenahealth Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for athenahealth Inc. and related companies with MarketBeat.com's FREE daily email newsletter.